Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2013-01-09 00:00:00+00:00 | AB | HSBC's China Deal in Trouble - Analyst Blog | HSBC Holdings plc 's ( HBC ) divestiture of its entire stake (15.6%) in Chinese insurance giant Ping An Insurance (Group) Company of China, Ltd to Thailand-based Charoen Pokphand Group has come to an unexpected halt after China Development Bank (CDB) expressed concerns regarding the funding for the deal.
In December 20... |
2013-01-08 00:00:00+00:00 | AB | Neutral Stance on Waddell & Reed - Analyst Blog | On December 31, 2012, we reiterated our long-term Neutral recommendation on Waddell & Reed Financial Inc. ( WDR ) based on the company's constantly improving assets under management (AUM) and robust capital deployment activities. However, the presence of substantial intangibles on its balance sheet and downward pressur... |
2013-01-08 00:00:00+00:00 | AB | AllianceBernstein Upped to Strong Buy - Analyst Blog | On January 5, Zacks Investment Research upgraded AllianceBernstein Holding L.P. ( AB ) to a Zacks #1 Rank (Strong Buy).
Why the Upgrade?
AllianceBernstein has been witnessing rising earnings estimates on the back of strong third-quarter 2012 results. Moreover, this well-known investment manager delivered positive earni... |
2013-01-07 00:00:00+00:00 | AB | Zacks #1 Rank Additions for Monday - Tale of the Tape | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Aeroflex Holding Corp. ( ARX )
AllianceBernstein Holding LP ( AB )
Atlas Energy LP ( ATLS )
Atmel Corp. ( ATML )
Big 5 Sporting Goods Corp. ( BGFV )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis Report
AEROFLEX HOLD... |
2012-12-07 00:00:00+00:00 | AB | Unisys Launched New Application - Analyst Blog | Unisys Corporation ( UIS ) recently unveiled its latest Agile Business (AB) Suite application software, Release 3.0, which can be used for Unisys ClearPath MCP and Microsoft Windows networks.
In today's world, there is a huge demand for creating and upgrading various mission-critical applications in an easier manner in... |
2012-11-27 00:00:00+00:00 | AB | AllianceBernstein Holding L.P. - Momentum | AllianceBernstein Holding L.P. ( AB ) posted impressive third quarter results late last month, which boosted 4 out of 5 total estimates for 2012 in the last 30 days. This Zacks #1 Rank (Strong Buy) global investment management firm has now surpassed the Zacks Consensus Estimate for three straight quarters. It also hit ... |
2012-10-09 00:00:00+00:00 | AB | Zacks #1 Rank Additions for Tuesday - Tale of the Tape | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Agrium Inc ( AGU )
AllianceBernstein Holding ( AB )
Amedisys Inc ( AMED )
American Woodmark ( AMWD )
BankFinancial Corp ( BFIN )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis Report
AGRIUM INC (AGU): Free Stock Anal... |
2012-10-03 00:00:00+00:00 | AB | Zacks #1 Rank Additions for Wednesday - Tale of the Tape | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
AllianceBernstein Holding LP ( AB )
The Allstate Corp. ( ALL )
American Science & Engineering, Inc. ( ASEI )
AMN Healthcare Services, Inc. ( AHS )
ArQule, Inc. ( ARQL )
View the entire Zacks #1 Rank List .
ALLIANCEBERNSTN (AB): Free Stock Analysis ... |
2012-09-27 00:00:00+00:00 | AB | Investors Continue To Lighten Up On Equities As Market Rallies | By Morningstar :
By Gregory Warren, CFA
While global equity markets have regained some of their footing during the third quarter, we don't believe this signals an end to market volatility. With Europe dealing with what has become an expanding debt crisis, most developed economies around the globe struggling to maintain... |
2012-08-01 00:00:00+00:00 | AB | Pre-Market Earnings Report for August 2, 2012 : APA, AEE, ANSS, ARIA, APO, ALE, AB, ABMD, AYR, AVD, ARQL, AGEN | The following companies are expected to report earnings prior to market open on 08/02/2012. Visit our Earnings Calendar for a full list of expected earnings releases.
Apache Corporation ( APA ) is reporting for the quarter ending June 30, 2012. The oil (us exp & production) company's consensus earnings per share foreca... |
2012-07-03 00:00:00+00:00 | AB | Fitch Maintains Outlook on Invesco - Analyst Blog | Fitch ratings have maintained its outlook on Invesco Ltd. ( IVZ ) at 'Stable' as a part of its review of four rated investment managers. Despite a decent first quarter 2012 results, the outlook remains unchanged as the agency is concerned about the impact of volatile equity markets on the company's financials.
Rational... |
2012-05-30 00:00:00+00:00 | AB | The Complete College Savings Solution | With student loan debt gradually becoming what some believe will be the next major financial crisis, saving for college has never been more important. Yet, as if figuring out the best investments for a regular portfolio weren't hard enough, parents saving for college have to navigate an even more complex array of diffe... |
2012-04-30 00:00:00+00:00 | AB | Can College Savings Be Saved? | Students are facing a crisis , as they struggle to afford the education they want and need. But while many focus on the impact of student-loan debt on young adults, few are looking at the other side of the coin -- namely, the incentives promoting college savings that in many cases aren't getting the job done.
The risin... |
2012-02-21 00:00:00+00:00 | AB | XL GROUP PLC (XL) - Profit Tracks | Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List - Stocks to Sell Now by 80% annually (+2% versus +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.
Here is a synopsis of why AB a... |
2012-02-21 00:00:00+00:00 | AB | Zacks Sell List Highlights: AllianceBernstein Holding LP, XL Group plc, General Cable and MeadWestvaco - Press Releases | For Immediate Release
Chicago, IL - February 21, 2012 - Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): AllianceBernstein Holding LP ( AB ) and XL Group plc ( XL ). Fur... |
2023-12-16 04:00:00+00:00 | ABBV | AbbVie lawsuit says rival Adcentrx stole anti-cancer secrets | By Blake Brittain
Dec 18 (Reuters) - Pharmaceutical company AbbVie ABBV.N has sued startup Adcentrx Therapeutics in California federal court, accusing it of stealing trade secrets to develop competing cancer-fighting antibodies by hiring away an AbbVie scientist.
AbbVie said in the lawsuit, filed on Friday, that the "v... |
2023-12-16 00:00:00+00:00 | ABBV | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the mar... |
2023-12-16 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-16 00:00:00+00:00 | ABBV | Better Income Stock: AT&T or AbbVie? | Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline in value over time unless the dividend is reinvested.
This may seem surprising, but ample evidence supports this claim. Onl... |
2023-12-16 00:00:00+00:00 | ABBV | 3 Biotech Stocks Most Wall Street Analysts Are Bullish About | The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind.
Phar... |
2023-12-16 00:00:00+00:00 | ABBV | 3 of the Most Attractive Dividend Stocks in the Pharma Space | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative opportunities for long-term investors.
Moreover, given the evergre... |
2023-12-14 00:00:00+00:00 | ABBV | 3 Fantastic Stocks That Could Enjoy a Santa Claus Rally | You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the S&P 500 often rises noticeably in the final five trading days of December and the first two days in January.
Three Motley... |
2023-12-13 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-12 00:00:00+00:00 | ABBV | Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago | How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants,... |
2023-12-12 00:00:00+00:00 | ABBV | US Consumer group seeks stronger warnings on Botox, similar treatments | By Leroy Leo
Dec 12 (Reuters) - Consumer advocacy group Public Citizen on Tuesday filed a petition with the U.S. Food and Drug Administration seeking to require makers of Botox and several similar injections to include stronger warnings about the risk of a potentially fatal muscle-paralyzing disease.
These injections, ... |
2023-12-12 00:00:00+00:00 | ABBV | AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors | With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by the competition. Specifically, it's following in the footsteps of compa... |
2023-12-11 00:00:00+00:00 | ABBV | Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although investors have some evidence of a possible economic recovery, they should still consider defensive stock picks. We just don’t know what will happen next. Moreover, certain data points contradict the optimistic narrative, thus warranting a reexamina... |
2023-12-11 00:00:00+00:00 | ABBV | Goldman Sachs Upgrades Abbvie (ABBV) | Fintel reports that on December 11, 2023, Goldman Sachs upgraded their outlook for Abbvie (NYSE:ABBV) from Neutral to Buy .
Analyst Price Forecast Suggests 15.97% Upside
As of November 27, 2023, the average one-year price target for Abbvie is 173.11. The forecasts range from a low of 136.35 to a high of $215.25. The av... |
2023-12-11 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-11 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-11 00:00:00+00:00 | ABBV | Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now | Barring some outliers, the US large cap pharmaceutical group has underperformed the broader markets this year.
In a setting characterized by formidable macro factors, such as economic growth trends and the trajectory of interest rates, Goldman Sachs’ Chris Shibutani says the group has shown it is “unstable on a defensi... |
2023-12-11 00:00:00+00:00 | ABBV | Health Rounds: New transplant approach may help more patients with sickle cell disease | By Nancy Lapid
Dec 12 (Reuters) - Hello Health Rounds readers! Today we highlight two high profile studies presented at the ongoing American Society of Hematology (ASH) meeting in San Diego. The first involves a new bone marrow transplant approach that could help more patients with severe sickle cell disease. The other... |
2023-12-11 00:00:00+00:00 | ABBV | ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns? | Healthcare companies are not completely immune to macro pressures but are generally more resilient compared to companies in other sectors. This is because of the essential nature of medicines and services offered by healthcare companies. Moreover, several healthcare companies are developing various treatments to addres... |
2023-12-10 00:00:00+00:00 | ABBV | 4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December | Many dividend stocks have sold off over the past year. Higher interest rates made lower-risk investments like bonds and bank CDs more attractive income-generating options. That weighed on the value of some high-quality dividend stocks, pushing up their yields.
On the bright side, income-seeking investors can lock in so... |
2023-12-10 00:00:00+00:00 | ABBV | AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? | Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
During 2023 investors have primarily focused on the company's declining revenue and profits, which stem from the loss of paten... |
2023-12-10 00:00:00+00:00 | ABBV | The 3 Best Cheap Stocks to Buy in December | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The rising market in 2023 has not lifted all boats. Some stocks look extremely cheap right now. This offers investors an opportunity to buy shares of great companies at distressed prices and ride them higher in coming months and years. While some stocks are... |
2023-12-09 00:00:00+00:00 | ABBV | Better Dividend Stock: AbbVie vs. Medical Properties Trust | Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past decade, and Medical Properties Trust (NYSE: MPW), a real estate investment trust (REIT) that focuses on hospitals, both offer di... |
2023-12-08 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-08 00:00:00+00:00 | ABBV | Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod | This week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. The FDA approved Novartis’ NVS rare blood disorder drug, Fabhalta (iptacopan) and Eli Lilly’s LLY Jaypirca for its second leukemia indication. J&J JNJ announced sales and earnings growth expe... |
2023-12-08 00:00:00+00:00 | ABBV | 3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows | Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near their lows. If the businesses are in good shape, that can make for great buying opportunities because when stock prices ar... |
2023-12-08 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block | For Immediate Release
Chicago, IL – December 8, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, NIKE, In... |
2023-12-08 00:00:00+00:00 | ABBV | AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? | These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.
The pharma giant's latest big buyout offer is for Cerevel Therapeutics (NASDAQ: CERE), a clinical-stage company developing treatments for schizophrenia ... |
2023-12-07 00:00:00+00:00 | ABBV | Health Care Sector Update for 12/07/2023: ABBV, CERE, JNJ, MRK, LLY | Health care stocks fell Thursday afternoon with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.7%.
In corporate news, AbbVie (ABBV) agreed to buy Cerevel Therapeutics (CERE) for $45 a share in cash, representing a total eq... |
2023-12-07 00:00:00+00:00 | ABBV | Healthcare Gems: 3 Essential Long-Term Stock Picks | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world’s most pressing issues from heart disease, Alzheimer’s, and cancer.
And to be sure, there are a number of ... |
2023-12-07 00:00:00+00:00 | ABBV | Health Care Sector Update for 12/07/2023: WBA, ABBV, CERE, JNJ, MRK, LLY, SLDB | Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.7%.
In corporate news, Walgreens Boots Alliance (WBA) said Thursday it is offering expanded COVID-19 and flu testing and ... |
2023-12-07 00:00:00+00:00 | ABBV | AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say | By Bhanvi Satija and Khushi Mandowara
Dec 7 (Reuters) - AbbVie's ABBV.N decision to buy Cerevel Therapeutics CERE.O before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.
North Chicago, Illinois-based Abb... |
2023-12-07 00:00:00+00:00 | ABBV | Bain scores over tenfold return with $8.7 billion Cerevel sale | By Greg Roumeliotis
Dec 7 (Reuters) - Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc CERE.O following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc ABBV.N, according to regulatory filings.
Boston-based Bain co... |
2023-12-07 00:00:00+00:00 | ABBV | Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout | Adds details from conference call and background throughout, analyst comment in paragraph 8
Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... |
2023-12-07 00:00:00+00:00 | ABBV | Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now. | It's too early to predict what the market will do next year, but there's one way to guarantee some stock market gains. And that's by investing in dividend stocks.
These players offer you passive income -- even when their share prices are falling or the general market is declining. They represent returns you can count o... |
2023-12-07 00:00:00+00:00 | ABBV | AbbVie to focus on smaller deals after buying spree | Adds details from conference call and background throughout, analyst comment in paragraph 8
Dec 7 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Thursday it intends to focus on smaller deals to support its growth through the next decade, after it struck two multibillion dollar deals in the past week to acquire Cereve... |
2023-12-07 00:00:00+00:00 | ABBV | Is AbbVie Stock a Buy Now? | Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster rheumatoid arthritis drug, which is losing patent protection. One example of this came in 2020 when it closed on a massive... |
2023-12-07 00:00:00+00:00 | ABBV | AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B | AbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel Therapeutics CERE, for $8.7 billion. This marks its second acquisition announcement in less than a fortnight.
The acquisition will strengthen AbbVie’s neuroscience pipeline by adding CERE’s novel pipeline candidates being studie... |
2023-12-06 00:00:00+00:00 | ABBV | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the WisdomTree U.S. High Dividend ETF (DHS) is a smart beta exchange traded fund launched on 06/16/2006.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the ma... |
2023-12-06 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-06 00:00:00+00:00 | ABBV | ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA | ImmunoGen, Inc. IMGN announced that the FDA accepted its supplemental biologics license application (“sBLA”), seeking to convert the accelerated approval for its sole marketed drug, Elahere (mirvetuximab soravtansine), to full approval for treating FRα-positive platinum-resistant ovarian cancer.
With the FDA granting a... |
2023-12-06 00:00:00+00:00 | ABBV | EXCLUSIVE-AbbVie nears roughly $8 billion for drug developer Cerevel-sources | NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
AbbVie is in talks to pay around $45 per share for Cerev... |
2023-12-06 00:00:00+00:00 | ABBV | 7 High-Dividend Stocks to Buy for a Lifetime of Passive Income | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
As investors, we always strive to build a well-balanced portfolio that can provide stability through various economic cycles. While high-flying growth stocks generate all the hype these days (and deservedly so), defensive dividend stocks remain essential to... |
2023-12-06 00:00:00+00:00 | ABBV | AbbVie to buy drug developer Cerevel for $8.7 billion | Adds details on the deal and background
Dec 6 (Reuters) - AbbVie ABBV.N said on Wednesday it would buy Cerevel Therapeutics CERE.O for a total equity value of about $8.7 billion.
AbbVie would acquire all outstanding shares of Cerevel for $45 per share in cash, representing a premium of 22% to Wednesday's close.
Cerevel... |
2023-12-06 00:00:00+00:00 | ABBV | AbbVie To Acquire Cerevel Therapeutics In $8.7 Bln Deal | (RTTNews) - AbbVie Inc. (ABBV) agreed to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, valuing the company at about $8.7 billion.
CERE closed Wednesday's regular trading at $36.93 up $1.34 or 3.77%. In the after-hours trading, the stock further gained $5.82 or 15.76%.
AbbVie will acquire Cerevel The... |
2023-12-06 00:00:00+00:00 | ABBV | EXCLUSIVE-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources | By David Carnevali
NEW YORK, Dec 6 (Reuters) - AbbVie Inc ABBV.N is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc CERE.O, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
The acquisition would come just days ... |
2023-12-05 00:00:00+00:00 | ABBV | Johnson & Johnson forecasts as much as 6% sales growth in 2024 | By Patrick Wingrove and Bhanvi Satija
Dec 5 (Reuters) - Johnson & Johnson JNJ.N on Tuesday forecast revenue growth of 5-6% for 2024, its first full year after hiving off its consumer health unit, on strong demand for cancer treatments Darzalex and Carvykti, and blockbuster psoriasis drug Stelara.
The company also forec... |
2023-12-05 00:00:00+00:00 | ABBV | AbbVie To Collaborate With BigHat To Discover Next-Gen Therapeutic Antibodies | (RTTNews) - AbbVie Inc. (ABBV) and BigHat Biosciences, Monday announced a research collaboration for next-generation therapeutic antibodies in oncology and neuroscience. The combination is expected to utilize BigHat's Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab.
As p... |
2023-12-05 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned +2.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Large C... |
2023-12-04 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-04 00:00:00+00:00 | ABBV | SPLG, HD, COST, ABBV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $278.0 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 427,100,000 t... |
2023-12-04 00:00:00+00:00 | ABBV | Analysts Anticipate MGC Will Reach $181 | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Mega Cap ETF (Symbol: ... |
2023-12-02 00:00:00+00:00 | ABBV | 2 Dividend Stocks to Buy and Hold Forever | Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a solid underlying business. So corporations that are able to consistently pay dividends and raise their payouts tend to ha... |
2023-12-02 00:00:00+00:00 | ABBV | 5 S&P 500 Stocks That Pay a Generous Dividend | The S&P 500 is the benchmark for the investing world. This well-known index comprises 500 of the largest and most visible corporations in the United States, the world's leading economy.
It's also a great hunting ground for phenomenal long-term stock ideas to fit any investing strategy. Dividend investors are a large gr... |
2023-12-01 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-12-01 00:00:00+00:00 | ABBV | Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More | This week, AbbVie ABBV announced a definitive agreement to acquire cancer biotech Immunogen at a premium valuation of $10.1 billion. Novartis NVS raised its mid-term sales growth outlook by 1%. Sanofi SNY and partner Regeneron’s second phase III chronic obstructive pulmonary disease (COPD) study showed that their block... |
2023-11-30 00:00:00+00:00 | ABBV | Health Care Sector Update for 11/30/2023: SNGX, IMGN, ABBV | Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%.
The iShares Biotechnology ETF (IBB) rose 1.1%.
In corporate news, Soligenix (SNGX) shares soared 183% after it said Thursday the US Food and Drug Administration has c... |
2023-11-30 00:00:00+00:00 | ABBV | AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio | Adds details throughout
Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments.
The drugmaker will pay $31.26 per ImmunoGen share in cash, representing a premium of 94.6% to the last closing price.
This transa... |
2023-11-30 00:00:00+00:00 | ABBV | AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln | (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
Under the terms of the transaction, ... |
2023-11-30 00:00:00+00:00 | ABBV | AbbVie Should Consider a Dividend Cut -- Here's Why | Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. These special companies have raised their dividends for at least 50 years, and AbbVie inherit... |
2023-11-30 00:00:00+00:00 | ABBV | Health Care Sector Update for 11/30/2023: IMGN, ABBV, XENE, CALT, XLV, IBB | Health care stocks were gaining premarket Thursday with the iShares Biotechnology ETF (IBB) advancing by 0.7% recently while the Health Care Select Sector SPDR Fund (XLV) was up 0.3%.
ImmunoGen (IMGN) was rallying by over 83% amid an agreement for AbbVie (ABBV) to acquire ImmunoGen and its ovarian cancer therapy Elaher... |
2023-11-30 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer | For Immediate Release
Chicago, IL – November 30, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, J&J JNJ, Eli... |
2023-11-30 00:00:00+00:00 | ABBV | Is it a Good Idea to Invest in Harpoon (HARP) Stock Now? | Harpoon Therapeutics HARP develops a novel class of T cell engagers, leveraging its proprietary Tri-specific T cell Activating Construct (TriTAC) platform. The company has made significant progress in the development of its key pipeline candidates, HPN328 and HPN217, in recent months.
In October, Harpoon Therapeutics p... |
2023-11-30 00:00:00+00:00 | ABBV | AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study | AbbVie ABBV announced top-line data from the single-arm phase II LUMINOSITY study on its investigational antibody-drug conjugate (ADC) candidate, telisotuzumab-vedotin (Teliso-V), in previously treated non-small cell lung cancer (NSCLC) patients with c-Met overexpression.
Management split its analysis between patients ... |
2023-11-30 00:00:00+00:00 | ABBV | Health Care Sector Update for 11/30/2023: JNJ, SNGX, ABBV, IMGN | Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.9%.
The iShares Biotechnology ETF (IBB) rose 1.1%.
In corporate news, Johnson & Johnson's (JNJ) MedTech unit said Thursday it has completed the $400 million acquisit... |
2023-11-30 00:00:00+00:00 | ABBV | This Combination of 3 Stocks Provides Monthly Income | Receiving steady dividend payouts is always a great feeling, as paydays are always the best. Of course, most dividends are paid quarterly.
However, by targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to get paid monthly.
For example –
The first stock p... |
2023-11-30 00:00:00+00:00 | ABBV | Why Abbvie Stock Popped Today | The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3% lift after the news was announced, contrasting quite favorably to the sagging S&P 500 index's 0.7% slip.
AbbVie is buying ... |
2023-11-30 00:00:00+00:00 | ABBV | AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker | Is AbbVie (NYSE:ABBV) a drugmaker to wager on now? I believe it's a very smart move to consider buying a few shares, especially in light of recent positive news about AbbVie. So, I am bullish on ABBV stock because there are identifiable catalysts that could lead to major share price appreciation.
AbbVie is a large Amer... |
2023-11-29 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-29 00:00:00+00:00 | ABBV | Medtronic Stock: Bull vs. Bear | Medtronic (NYSE: MDT) is a medical device giant that has generated billions of dollars in earnings over time thanks to its diabetes, cardiovascular, neuroscience, and medical-surgical platforms. The company's growth stagnated in recent years, though, so management set out on a path to transform the business -- with a f... |
2023-11-29 00:00:00+00:00 | ABBV | 4 Large Drug Stocks to Watch as IBD Market Gains Traction | In recent years, there has been a surge in the prevalence of gastrointestinal disorders, particularly inflammatory bowel disease (IBD). It includes two conditions, Crohn's disease (“CD") and ulcerative colitis (“UC”), both characterized by chronic inflammation in the gastrointestinal tract.
There has been a consistent ... |
2023-11-29 00:00:00+00:00 | ABBV | Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tomorrow. Today’s economy is marked by a lot of unsteadiness.... |
2023-11-28 00:00:00+00:00 | ABBV | 3 Defensive Dividend Stocks to Protect Your Portfolio | After a historically bad performance during the first half of the year, dividend stocks have come under quite a bit of scrutiny lately. A new Bloomberg analysis of the dividend stock underperformance in 2023 observed, “Investors wanted exposure to companies with a history of paying out profits as a precaution amid the ... |
2023-11-28 00:00:00+00:00 | ABBV | Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? | Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transpare... |
2023-11-28 00:00:00+00:00 | ABBV | AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag | AbbVie ABBV along with partner Genmab GMAB announcedthat the FDA has granted breakthrough therapy designation (“BTD”) to epcoritamab for treating adults with relapsed or refractory (“R/R”) follicular lymphoma (“FL”), after two or more lines of therapies.
The FDA grants BTD to expedite the development and review of ther... |
2023-11-27 00:00:00+00:00 | ABBV | AbbVie, Genmab Issue Positive FDA, EMA Updates For Epcoritamab To Treat R/R Follicular Lymphoma | (RTTNews) - Drug makers AbbVie (ABBV) and Genmab (GMAB) announced Monday positive updates from the U.S. Food and Drug Administration or FDA and European Medicines Agency or EMA for epcoritamab (Epkinly / Tepkinly) for relapsed or refractory (R/R) follicular lymphoma (FL).
Epcoritamab, co-developed by AbbVie and Genmab,... |
2023-11-27 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-26 00:00:00+00:00 | ABBV | 3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later | Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends, they also miss out on income.
Three Motley Fool contributors think they've found fantastic dividend stocks to buy sooner ra... |
2023-11-24 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-24 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned -4.6% over the past month versus the Zacks S&P 500 composite's +8.2% change. The Zacks ... |
2023-11-24 00:00:00+00:00 | ABBV | Could AbbVie Stock Help You Become a Millionaire? | If you want an investment to make you a millionaire, you need three things. The first is some decent money to invest in the stock market, ideally at least $20,000. The second is time and patience -- big returns don't come quickly unless you're taking on significant risks. The third is an above-average return, which com... |
2023-11-23 00:00:00+00:00 | ABBV | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | Launched on 06/16/2006, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.07 billion, making it one of the average sized E... |
2023-11-23 00:00:00+00:00 | ABBV | Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While it’s always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelling. You can get your growth and also enjoy dividend payments... |
2023-11-22 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-11-21 00:00:00+00:00 | ABBV | 3 "Boring" Stocks That Could Make You Rich | You don't have to invest exclusively in the so-called "exciting" stocks to get rich. Actually, the stocks that generate the most excitement for investors over the short term can often be big losers over the long term.
Of course, the amount of wealth needed to feel rich will be different for different investors. And no ... |
2023-11-21 00:00:00+00:00 | ABBV | Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now | All eyes have been on Eli Lilly (NYSE: LLY) in recent times as it prepared to increase its earnings potential in the billion-dollar weight-loss treatment market. Lilly already has generated blockbuster revenue from Mounjaro, a diabetes drug doctors have also prescribed for weight loss. And now growth may really take of... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.